MOTS-c common uses, half-life, side effects and more
Also known as MOTS
About
MOTS-c is a 16-amino-acid peptide whose gene sits inside mitochondrial DNA. People inject it for insulin sensitivity, exercise capacity, and longevity goals. No regulator has approved it anywhere. Vials sold online are research-market material. Anyone tested in sport should know it is banned by name all year round.
Common uses
- Insulin sensitivity and metabolic flexibility
- Exercise capacity and fatigue resistance
- Body composition support during a calorie deficit
- Longevity and mitochondrial health protocols
Frequency
Daily to twice weekly in blocks of 4 to 10 weeks
Dosing
Reported doses run from about 0.5 to 5 mg injected under the skin. People take them daily to twice a week for roughly 1.5 to 15 mg across a week. There is no settled protocol and users openly disagree about whether small daily doses beat larger ones twice weekly. One community guide starts at 200 to 1,000 mcg daily. That is below what many community members report running. Some switch to a whole 10 mg vial into muscle to escape skin reactions rather than for any dosing reason. A widely copied schedule of 5 mg every 5 days began on a vendor affiliate page in 2022 and no community member reports running it. The animal doses behind the popular claims scale to roughly 20 to 600 mg a week in an adult.
Administration
- A 10 mg vial in 1 mL of water makes 2 mg read as 20 units and 5 mg as 50 units on an insulin syringe
- Experienced users tell newcomers to start low and keep antihistamines on hand because of the skin reactions
- Blocks of 4 to 10 weeks are more common than continuous use
- A purity figure on a certificate gives the share of the peptide material that is the main compound and says neither which compound it is nor how much is in the vial
- A mass test confirms a peptide of the right weight but cannot tell the right 16-amino-acid sequence from the same amino acids in another order or from a swap of its leucine and isoleucine
- People with welts report fewer reactions after dosing less often or mixing with more water
Half-life
The half-life of MOTS-c is estimated at about 1.5 hours. A research review inferred 1 to 2 hours from how fast the body clears MOTS-c it released itself after exercise but no study has followed blood levels after a dose. Each dose clears from the blood within about half a day.
Storage
Mixed MOTS-c can turn cloudy or set into a gel at the strengths people commonly mix. Warmth and time make that more likely. A shorter analog stayed clear for 6 days in the fridge but gelled within hours to days at room temperature. No reputable source treats a cloudy or gelled vial as fully dissolved.
Side effects
- Itchy welts and lumps at the injection site are the most reported problem and several people describe them lasting a week
- Itching and redness can also come on within minutes of a shot and fade within 1 to 4 hours
- Community members repeatedly report histamine-type reactions and one described a near-anaphylactic response
- An anti-doping agency lists raised heart rate, palpitations, injection site irritation, insomnia, immune reactions, and fever as effects reported by people who buy it online
- About 10 community members report tiredness after a dose
- Blood sugar fell about 6 percent over 4 weeks in a human study of a related molecule
How it works
The gene for MOTS-c sits inside the 12S ribosomal RNA gene of mitochondrial DNA. The peptide cannot be built inside the mitochondrion itself. Human mitochondria carry no transfer RNA that reads two of its codons. The instructions must therefore reach the main body of the cell and nobody has shown how that happens. Adding the peptide switches on an energy sensor called AMPK. A Copenhagen group with no ties to the discovering laboratory confirmed the effect needs AMPK present to work. A 2015 experiment proposed that MOTS-c blocks a folate pathway until a natural AMPK trigger builds up. Nobody has measured that step again since. That includes the laboratory that proposed it. A 2024 paper from that same laboratory named a different primary target and did not mention AMPK anywhere. No cell-surface receptor has been found.
Research quality
Nobody has completed a study giving MOTS-c to a person. A 2026 FDA review found no toxicity study, no reproductive or cancer testing, and no measurement of how the peptide behaves in a living body. That review also states the molecular targets remain unknown. A human trial in this family used a different engineered molecule, ran 4 weeks, never reached a journal, and left both its antibody and its pharmacokinetic results unpublished before the company dissolved. Rodent work on glucose handling, exercise capacity, and muscle function has been repeated in several countries. One 15 mg per kg dose gave untrained mice 12 percent more running time. The human studies measure only the peptide people already make. Antibody tests found the body's own MOTS-c rose in muscle and blood after a single cycling session in 10 inactive young men. A second human study found only a trend after 45 minutes of cycling. An accredited doping laboratory could not confirm the antibody test that nearly all of them rely on. Reported blood levels across the literature differ by about four orders of magnitude. A registered trial of the peptide appeared in 2026 under a seller whose registry account also holds an admitted mock protocol.
Warnings
- MOTS-c is named on the anti-doping prohibited list, is banned in and out of competition all year, and sits in a class with no reduced-sanction route for accidental use
- Injecting a peptide the body already makes can raise antibodies against the body's own supply and the FDA named this its main concern
- Whether MOTS-c helps or harms aging cells is unsettled and reviews group it with its sibling peptide as a pathway tumors could exploit
- No toxicity, fertility, pregnancy, or cancer study of any kind has been done
- Vials carry almost no independent identity testing and a purity number does not prove what is inside
- There is no lawful route to MOTS-c through a US compounding pharmacy
Sources (27)
-
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis, the discovery paper and the source of the folate and AICAR mechanism
Cell Metabolism 2015 (PMID 25738459)
-
MOTS-c nuclear translocation and adaptive nuclear gene expression, from the same laboratory as the discovery paper
Cell Metabolism 2018 (PMID 29983246)
-
MOTS-c as an exercise-induced regulator of physical decline and muscle homeostasis, the source of the four-hour exercise response in ten young men
Nature Communications 2021 (PMID 33473109)
-
MOTS-c modulates skeletal muscle function by directly binding and activating CK2, which names a different primary target and does not mention AMPK
iScience 2024 (PMID 39559755)
-
Independent test of whether MOTS-c improves muscle mitochondrial function through AMPK, carried out with no authors from the discovering laboratory
Free Radical Biology and Medicine 2026 (PMID 41520850)
-
A pro-diabetogenic mtDNA polymorphism in MOTS-c, which tested the K14Q variant against exceptional longevity in 736 Japanese centenarians and did not support the longevity hypothesis
Aging 2021 (PMID 33468709)
-
Mass spectrometric determination of MOTS-c in plasma, the accredited doping-laboratory method that could not confirm the antibody-test concentrations
Rapid Communications in Mass Spectrometry 2019 (PMID 30394592)
-
Evidence of natural selection in the mitochondrial-derived peptides humanin and SHLP6, whose codon-bias analysis found no such signature for MOTS-c
Scientific Reports 2023 (PMID 37644144)
-
Mitochondrial-derived peptides exacerbate senescence, a review reporting that MOTS-c and humanin both worsen the inflammatory output of aging cells
Rejuvenation Research 2018 (PMID 30058454)
-
FDA briefing document evaluating MOTS-c free base and MOTS-c acetate for the 503A bulk drug substances list, which proposes not adding them
US Food and Drug Administration, 11 May 2026
-
Certain bulk drug substances for use in compounding that may present significant safety risks, which names MOTS-c for immunogenicity and characterization concerns
US Food and Drug Administration
-
Prohibited List section S4.4.1, which names mitochondrial open reading frame of the 12S rRNA-c among AMPK activators and classes the section as non-Specified
World Anti-Doping Agency 2026
-
MOTS-c peptide status in sport, the source of the four self-reported effects
US Anti-Doping Agency
-
Phase 1a and 1b trial of CB4211, an engineered analog rather than MOTS-c itself, whose results were never published or posted
ClinicalTrials.gov NCT03998514
-
Cognitive Vitality appraisal of MOTS-c, which records that it has never been clinically tested in humans and lists its half-life as not available
Alzheimer's Drug Discovery Foundation 2025
-
Test tube stability of MOTS-c in human, monkey, and mouse plasma
US Patent 11,111,271 B2
-
Formulation patent for a MOTS-c analog showing cloudiness and gelling at room temperature and none in the fridge
US Patent 11,517,608 B2
-
FDA briefing document on MOTS-c noting missing solubility data and a possible tendency to aggregate
US Food and Drug Administration 2026
-
First-hand reports of immediate and delayed injection-site reactions to MOTS-c
Peptide Critic community forum 2026
-
Control strategies for synthetic therapeutic peptide APIs, part 1, analytical considerations, by the USP Therapeutic Peptides Expert Panel
Pharmaceutical Technology 2014
-
MOTS-c protein entry giving the 16-amino-acid sequence
UniProt A0A0C5B5G6
-
Explainer on peptide purity and net peptide content
Peptide manufacturer knowledge center
-
Explainer on what a peptide purity figure measures
Custom peptide manufacturer
-
Quality and safety analysis of semaglutide products sold online without a prescription, in which vials claiming 99 percent purity held 7.7 to 14.4 percent semaglutide by weight (Ashraf et al.)
Journal of Medical Internet Research 2024 (PMID 39509151)
-
A single MOTS-c dose improved running time in untrained mice (Hyatt et al.)
Physiological Reports 2022 (PMID 35808870)
-
Acute endurance exercise and circulating mitochondrial-derived peptides in humans (von Walden et al.)
Journal of Applied Physiology 2021 (PMID 34351816)
-
First-hand reports of tiredness after MOTS-c doses
Reddit peptides community posts